PIP Search Page

Displaying 241 - 260 of 478

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check Sort descending	Date Published
MHRA-100701-PIP01-22-M01 (update)	Outer Membrane Vesicles (OMV) from N. meningitidis Strain NZ 98/254 Recombinant Neisseria meningitis group B Protein 936-741 Meningococcal group W-135 oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein Meningococcal group A oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein Meningococcal group C oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein Recombinant Neisseria meningitis group B Protein 287- 953 Recombinant Neisseria meningitis group B Protein 961c Meningococcal group Y oligosaccharides conjugated to Corynebacterium diphtheriae CRM197 protein	Prevention of meningococcal meningitis		Vaccines	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100709-PIP01-22-M02 (update)	Rozanolixizumab	Treatment of myasthenia gravis		Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100799-PIP01-22-M01 (update)	BEDAQUILINE FUMARATE	Treatment of multi-drug resistant tuberculosis	Sirturo	Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100323-PIP01-21-M02 (update)	SAXAGLIPTIN	Treatment of Type 2 Diabetes Mellitus	Onglyza Onglyza Onglyza Onglyza Onglyza	Endocrinology-Gynaecology-Fertility-metabolism	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100349-PIP01-21-M02 (update)	Rezafungin acetate	Treatment of invasive candidiasis	Rezzayo 200 mg powder for concentrate for solution for infusion	Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100447-PIP01-22-M02 (update)	Tirzepatide	Treatment of Type 2 Diabetes Mellitus	Mounjaro Mounjaro	Endocrinology-Gynaecology-Fertility-metabolism	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100709-PIP01-22-M01 (update)	rozanolixizumab	Treatment of myasthenia gravis		Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100714-PIP01-22-M01 (update)	Gepotidacin	Treatment of uncomplicated urogenital gonorrhoea (GC)		Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100720-PIP01-22-M01 (update)	Gepotidacin	Treatment of uncomplicated urinary tract infections		Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100475-PIP01-22-M01 (update)	Neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid Neisseria meningitidis serogroup C polysaccharide conjugated to tetanus toxoid Neisseria meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid Neisseria meningitidis serogroup W polysaccharide conjugated to tetanus toxoid	Prevention of invasive meningococcal disease	MenQuadfi MenQuadfi	Vaccines	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100351-PIP01-21-M01 (update)	DOLUTEGRAVIR RILPIVIRINE	Treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection.	JULUCA JULUCA JULUCA JULUCA JASUPA Juluca 50mg/25mg film-coated tablets JULUCA JULUCA JULUCA JULUCA JULUCA JULUCA JULUCA JULUCA JULUCA JULUCA JULUCA JULUCA JULUCA	Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100130-PIP01-21-M02 (update)	BUPIVACAINE	Postsurgical analgesia	EXPAREL liposomal EXPAREL EXPAREL EXPAREL EXPAREL	Pain	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100717-PIP01-22-M01 (update)	RISDIPLAM	Treatment of spinal muscular atrophy	Evrysdi Evrysdi Evrysdi Evrysdi Evrysdi Evrysdi Evrysdi Evrysdi	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100164-PIP01-21-M02 (update)	Nirmatrelvir RITONAVIR	Treatment of coronavirus disease 2019 (COVID-19) Prevention of Coronavirus Disease 2019 (COVID-19)	Paxlovid Paxlovid Paxlovid Paxlovid Paxlovid Paxlovid	Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100148-PIP01-21-M03 (update)	LENVATINIB MESILATE	Treatment of all conditions included in the category of malignant neoplasms except haematopoietic and lymphoid tissue neoplasms, papillary thryoid cancer, follicular thyroid cancer and osteosarcoma	Lenvima Lenvima Kisplyx Kisplyx	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	30/06/2023
MHRA-100641-PIP01-22-M02 (update)	DURVALUMAB	Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue)	IMFINZI IMFINZI	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	14/08/2023
MHRA-100297-PIP01-21-M01 (update)	Human, recombinant, non-fucosylated IgG1k monoclonal antibody targeting OX-40 receptor on activated T cells (rocatinlimab)	Treatment of atopic dermatitis		Dermatology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	24/08/2023
MHRA-100687-PIP01-22-M01 (update)	OBINUTUZUMAB	Treatment of systemic lupus erythematosus	Gazyvaro Gazyvaro	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	24/08/2023
MHRA-100807-PIP01-22-M01 (update)	RIMEGEPANT SULFATE	Treatment of migraine headaches	Vydura	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	24/08/2023
MHRA-100276-PIP01-21-M02 (update)	BRODALUMAB	Treatment of psoriasis	Kyntheum Lumicef Siliq	Dermatology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	24/08/2023

Download XLSX

Search Filters: